{"result": "(\"entity\"<|>MELAS<|>EVENT<|>MELAS is a syndrome characterized by a variety of clinical manifestations including neurological issues, diabetes mellitus, and gastrointestinal symptoms, primarily due to mitochondrial dysfunction.)\n##\n(\"entity\"<|>DIABETES MELLITUS<|>EVENT<|>Diabetes Mellitus is a condition that is prevalent among patients with MELAS, often developing around the age of 37-38 years and associated with insulin deficiency.)\n##\n(\"entity\"<|>MITOCHONDRIAL DYSFUNCTION<|>EVENT<|>Mitochondrial dysfunction is a key factor in the development of MELAS and its associated symptoms, including neurological and metabolic issues.)\n##\n(\"entity\"<|>NEW CASTLE<|>GEO<|>New Castle is referenced in the context of a scale used to assess the severity of mitochondrial diseases in adults.)\n##\n(\"relationship\"<|>MELAS<|>DIABETES MELLITUS<|>MELAS is associated with a higher prevalence of Diabetes Mellitus among its patients<|>8)\n##\n(\"relationship\"<|>MELAS<|>MITOCHONDRIAL DYSFUNCTION<|>Mitochondrial dysfunction is the underlying cause of the MELAS syndrome<|>9)\n##\n(\"relationship\"<|>DIABETES MELLITUS<|>MITOCHONDRIAL DYSFUNCTION<|>Diabetes Mellitus in MELAS patients is often due to mitochondrial dysfunction<|>7)\n##\n(\"relationship\"<|>MELAS<|>NEW CASTLE<|>The severity of MELAS symptoms can be assessed using the New Castle scale<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de ictus-like antes de los 40 años.\n      2. Encefalopatía con crisis epilépticas o demencia.\n      3.  Acidosis láctica (debido a la heteroplasmia de las mitocondrias se requiere\n      muestra de sangre y orina) o fibras rojas rotas en la biopsia muscular.\n\n\n\n         El cuadro clínico es variado (Tabla 1) y consiste en la afectación neurológica\nhasta en el 90% de los pacientes; episodios de ictus-like (84-99%), epilepsia (71-96%),\nhipoacusia neurosensorial (71-77%), demencia (40-90%), neuropatía periférica (22-77%).\nAdemás, existe afectación muscular, siendo la miopatía el síntoma cardinal, cursando\ntambién con intolerancia al ejercicio y debilidad muscular (73-100%)10. La acidosis láctica\nestá presente hasta en el 94% de todos los pacientes y por ello se considera un criterio\ndiagnóstico3 .\n         Entre las manifestaciones más prevalentes también se encuentran las endocri-\nnas: diabetes      mellitus (DM) (21-33%), talla baja (33-82%), deficiencia de hormona de\ncrecimiento, hipotiroidismo, hipogonadismo hipogonadotropo e hipoparatiroidismo.\n\n\n\n         En un estudio de cohortes publicado en 2018 11 , se describe que la DM es más pre-\nvalente en el síndrome de MELAS en comparación con otras enfermedades mitocondria-\nles. En esta cohorte, la prevalencia en mayores de 18 años alcanza el 24,4% y la mutación\nmás asociada, dentro del síndrome de MELAS, fue la 3246A>G (39.8%; IC 29.5-50.8%).\n\n\n\n                                                                                              45\n---\n              Este tipo de DM se caracteriza porque se desarrolla con una media de edad de\n    37-38 años12 , suele ser debida a un déficit de insulina más que a una resistencia a la\n    misma, aunque se dan ambos mecanismos fisiopatológicos. Además, aproximadamente\n    el 20% se diagnostica de forma aguda llegando a alcanzar una cetoacidosis en el 8% de\n    los casos, aunque tan solo el 13% de los portadores de la mutación 3246A>G requieren\n    insulina al diagnóstico. Del 87% restante, la DM se desarrolla insidiosamente hasta que\n    súbitamente requiere insulina. Otra de las observaciones es que un IMC más bajo se\n    correlaciona con una mayor probabilidad de aparición de DM, más rápida instauración\n    de tratamiento con insulina y peores cifras de HbA1c. Al contrario que en la DM tipo 2, la\n    metformina está contraindicada por el riesgo de acidosis, pero el primer escalón tam-\n    bién es la dieta y el ejercicio. Posteriormente, la segunda línea de tratamiento son los\n    inhibidores de la DPP-4 y/o análogos de GLP-1 y por último la insulina13 .\n              En cuanto a las alteraciones gastrointestinales, han sido descritas prospectiva-\n    mente hasta en el 64% de los pacientes con MELAS14 . Estos síntomas incluyen: dis-\n    confort abdominal, vómitos, estreñimiento, diarrea, gastroparesia, pseudo-obstrucción\n    intestinal y episodios de pancreatitis recurrentes15 . Por otro lado, un estudio que inclu-\n    yó a 92 pacientes evidenció que los síntomas gastrointestinales aumentan el riesgo de\n    padecer malnutrición en portadores de la mutación m.3243A>G. En el 14% de la cohorte,\n    el IMC fue inferior a 20 kg/m2 y, además, en aquellos con una puntuación elevada en la\n    escala de gravedad de enfermedades mitocondriales de adultos de New Castle (NMDAS)\n    este porcentaje aumentó hasta el 31%.\n\n\n\n              A pesar de la frecuencia de manifestaciones digestivas y desnutrición en los\n    pacientes con MELAS, la literatura es escasa en cuanto a su manejo, limitándose exclu-\n    sivamente a estudios de cohortes sobre la descripción de los síntomas, pero sin indicar\n    un tratamiento específico por la heterogeneidad del cuadro16 .\n    Tabla 1. Manifestaciones clínicas del síndrome de MELAS10\n                                   Neurologicas (>90%): Cefaleas recurrentes\n                                   Episodios de Stroke -like (84- 999) . Alteraciones\n                                   neurologicas focales autolimitadas y de duracion\n                                   incierta: Fundamentalmente occipitales (VISUALES):\n                                   Epilepsia (71-96%) con presentacion heterogenea:\n                                   Hipoacusia neurosensorial (71-77%) . Demencia (40-90%) .\n                                   Neuropatia per\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}